Camber announces plans for 2025 market intros

Camber is reflecting on its 2024 milestones, noting that it launched 36 new generic products, filed 35 new ANDAs and received 53 ANDA approvals. 

“These milestones have allowed Camber to provide affordable medications to a growing patient population,” the company said.

Camber also made strategic investments in its workforce, welcoming new talent across its customer service, warehouse operations, supply chain and OTC business teams.

[Read more: Camber debuts generic Tarceva]

“As we look ahead to 2025, we are energized by the opportunities," Camber said.

The company is set to launch a lineup of specialty medications and generic oncology products, with plans to introduce 45 to 50 new generic products throughout the year.

Camber also said it is investing in the future of its operations, including constructing an onsite refrigerated warehouse to accommodate its growing injectable portfolio. "Additionally, Camber is expanding its operations and service teams and continually improving how it can serve its customers and the patients who depend on them," the company said.

Camber said this success wouldn’t be possible without the hard work of its associates, the trust of its customers and the support of its partners. "Thank you for being a part of our journey. Here’s to a successful, innovative and impactful 2025!,” Camber said.